To include your compound in the COVID-19 Resource Center, submit it here.

Ovid reports Phase I data for CYP46A1 inhibitor OV935

Ovid Therapeutics Inc. (NASDAQ:OVID) reported data from a pair of Phase I trials in 88 healthy

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE